Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results